Novavax Inc Stock Price, News & Analysis

Novavax (NASDAQ: NVAX) has announced its participation in two major upcoming investor conferences in June 2025. The company will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2025, from 2:00-2:30 PM ET in New York. Additionally, Novavax will deliver a presentation at the Goldman Sachs 46th Annual Global Healthcare Conference on June 11, 2025, from 2:00-2:35 PM ET in Miami Beach.

Both events will be webcasted and available on Novavax's investor relations website at ir.novavax.com, with replays accessible for 30 days following the events.

The FDA has approved Novavax's (NVAX) Biologics License Application for Nuvaxovid™, its COVID-19 vaccine. The approval is for adults 65+ and individuals 12-64 with high-risk conditions. This triggers a $175 million milestone payment from Sanofi under their May 2024 collaboration agreement, which includes future tiered royalties. Nuvaxovid is the only recombinant protein-based, non-mRNA COVID-19 vaccine available in the U.S. The FDA has requested a new Phase 4 trial for individuals 50-64 without high-risk conditions. Novavax plans to deliver the 2025-2026 COVID-19 vaccine formula this fall through Sanofi, pending strain recommendations. The vaccine has been available under Emergency Use Authorization since July 2022 and has full market approvals in multiple countries.

Novavax (NVAX) reported strong Q1 2025 financial results with total revenue of $667 million, compared to $94 million in Q1 2024. The company posted a net income of $519 million, a significant improvement from a net loss of $148 million in the same period last year. Key highlights include: • Raised 2025 revenue guidance to $975-$1,025 million • Received positive FDA feedback on COVID-19 BLA, with potential $175 million milestone payment upon approval • SHIELD-Utah study showed Nuvaxovid had 39% fewer reactogenicity symptoms vs mRNA vaccine • Strengthened partnership with Takeda in Japan, including $20 million upfront payment • Maintained 2025 guidance for R&D and SG&A expenses at $475-$525 million The company continues to advance its three strategic priorities: optimizing Sanofi partnership, developing new partnerships, and advancing early-stage pipeline development.

Novavax (NASDAQ: NVAX) has announced its participation in the upcoming BofA Securities 2025 Health Care Conference in Las Vegas, Nevada. The company will engage in a fireside chat on Wednesday, May 14, 2025, from 3:00 to 3:30 PM PT. Additionally, Novavax will conduct investor meetings during the conference. The fireside chat will be accessible via webcast on the company's investor relations website at ir.novavax.com, with a replay available for 30 days following the event.

Novavax (NASDAQ: NVAX) has announced improved terms for its collaboration and license agreement with Takeda for Nuvaxovid®, their protein-based COVID-19 vaccine, in Japan. The amended agreement includes enhanced financial terms such as an upfront payment, payment for the 2024/2025 season, and annual milestone payments tied to regulatory approvals. Additionally, Novavax will receive royalties on net sales for each season moving forward.

The agreement ensures continued availability of Nuvaxovid®, a non-mRNA COVID-19 vaccine, in Japan - the world's third-largest pharmaceutical market. According to CEO John C. Jacobs, this strengthened partnership validates Novavax's technology platform and Matrix-M® adjuvant while positioning the company as a partner of choice.

Novavax (NASDAQ: NVAX) has scheduled its first quarter 2025 financial results and operational highlights conference call for May 8, 2025, at 8:30 a.m. Eastern Time. Participants can join through phone registration or direct dial-in, with connection recommended 10 minutes before the start time.

A replay of the conference call will be available from 11:30 a.m. ET on May 8 until 11:59 p.m. ET on May 15, 2025. The webcast replay will remain accessible through June 7, 2025, on the company's investor relations website.

Novavax has appointed Charles Newton as an independent director to its Board of Directors. Newton, currently serving as Chief Financial Officer of Lyell Immunopharma, brings extensive experience in healthcare investment banking and public markets to the role.

Newton's background includes leadership positions at major financial institutions including Bank of America Merrill Lynch, Credit Suisse, and Morgan Stanley. He currently serves on the boards of Coherus BioSciences and 2seventy bio. Newton holds a BS in Finance from Miami University and an MBA from The Tuck School at Dartmouth College.

The appointment aligns with Novavax's corporate growth strategy, which focuses on developing strategic partnerships for their R&D assets and Matrix-M® adjuvant technology platform. CEO John C. Jacobs emphasized that Newton's expertise in corporate finance and capital markets will be valuable for the company's future direction.

Novavax (NVAX) has announced preliminary results from the SHIELD-Utah study comparing its COVID-19 Vaccine (2024-2025 Formula) targeting the JN.1 strain with Pfizer-BioNTech's mRNA vaccine. The real-world study, conducted between September-December 2024, demonstrated significantly lower reactogenicity in Novavax recipients.

Key findings show Novavax recipients experienced an average of 1.7 symptoms versus 2.8 in Pfizer-BioNTech recipients. Only 24.2% of Novavax recipients reported Grade 2 or higher symptoms compared to 43.8% for Pfizer-BioNTech. Local reactogenicity events were 12.5% lower in Novavax recipients.

The study, conducted at University of Utah Health with 219 Novavax and 369 Pfizer-BioNTech recipients, also revealed reduced impact on daily activities. Novavax recipients reported fewer hours of missed work (0.7 vs 1.4h) and less productivity impact (0.8 vs 2.4h) compared to Pfizer-BioNTech recipients.

Novavax (NVAX) announced significant changes to its Board of Directors. James Young, PhD, who served as Chair since 2011, is retiring effective March 10, 2025. Margaret McGlynn, RPh, a board member since 2020, has been appointed as the new Chair. Additionally, John Shiver, PhD, joins as an independent director.

During Young's 15-year tenure, Novavax achieved several milestones, including the acquisition of Isconova and Matrix-M™ adjuvant, global approvals and commercialization of its first COVID-19 vaccine, and partnership with Sanofi in 2024. The company is pursuing a new corporate growth strategy focused on strategic partnerships for R&D assets and Matrix-M™ adjuvant.

McGlynn brings experience as former President of Merck Vaccines and Infectious Disease and CEO of International AIDS Vaccine Initiative. Dr. Shiver contributes over 30 years of vaccine, biologics, and RNA therapeutics expertise, having led teams developing vaccine candidates for over 40 diseases.